Tags : CDx

MedTech

QIAGEN Launches Therascreen BRAF Test as CDx to a BraftovI

Shots: QIAGEN launches its therascreen BRAF V600E RGQ PCR Kit as a CDx to Pfizer’s Braftovi (encorafenib) in combination with Lilly’s Erbitux (cetuximab) for the treatment of patients with m-CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy The therascreen BRAF V600E kit runs on QIAGEN’s Rotor-Gene Q MDx […]Read More

MedTech

Promega Signs a Worldwide Agreement with Merck to Develop MSI

Shots: Promega and Merck collaborated to develop Promega’s microsatellite instability (MSI) technology as an on-label solid tumor CDx for use with Merck’s Keytruda (pembrolizumab)  Promega’s Microsatellite Instability technology measures the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) occurring in a solid-tumors, used to characterize tumors and guide […]Read More

MedTech

Eli Lilly Signs an Agreement with Thermo Fisher to Develop

Shots: The companies collaborated to develop companion diagnostic utilizing Thermo Fisher’s Oncomine Dx Target Test for the identification of RET-altered NSCLC and thyroid cancer patients who may be treated with Lilly’s LOXO-292 Thermo Fisher will retain rights to commercialize its test in all markets including the US, EU and Japan. Post validation, Thermo Fisher will […]Read More

MedTech

Resolution Bioscience Collaborates with Janssen to Develop Cell-Free DNA CDx

Shots: Janssen and Resolution Bioscience develops Resolution’s HRD liquid biopsy test as a companion diagnostic for Janssen’s Niraparib, being investigated for the treatment of metastatic castration-resistant prostate cancer The Resolution HRD assay will allow Janssen to identify patients with prostate cancer who may benefit from Niraparib therapy. In 2016, Janssen got exclusive WW license from […]Read More

MedTech

Roche Launches Ventana HER2 Dual ISH CDx for the Identification

 Shots: Roche’s Ventana HER2 Dual ISH DNA Probe Cocktail assay is used to detect HER2 biomarker in breast and gastric cancer patients receiving Herceptin (trastuzumab) The approval of Ventana HER2 Dual ISH assay supports Roche’s personalized healthcare sector by providing techniques to diagnose breast and gastric cancer The Ventana HER2 assay is fully automated on […]Read More